Fate Therapeutics Inc. (FATE) Sees Large Volume Increase
Fate Therapeutics Inc. (NASDAQ:FATE) shares saw strong trading volume on Tuesday . 270,744 shares traded hands during mid-day trading, an increase of 70% from the previous session’s volume of 158,905 shares.The stock last traded at $3.18 and had previously closed at $3.00.
A number of analysts have recently weighed in on the company. Zacks Investment Research cut Fate Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 12th. BMO Capital Markets set a $4.00 price objective on Fate Therapeutics and gave the stock a “buy” rating in a research report on Monday, August 8th. Leerink Swann reissued an “outperform” rating and issued a $4.00 price objective on shares of Fate Therapeutics in a research report on Tuesday, June 21st. Finally, HC Wainwright reissued a “buy” rating on shares of Fate Therapeutics in a research report on Tuesday, August 9th. Eight equities research analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and an average target price of $6.29.
The stock’s market capitalization is $92.17 million. The company has a 50 day moving average price of $2.62 and a 200 day moving average price of $2.02.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/fate-therapeutics-inc-fate-sees-large-volume-increase.html
Fate Therapeutics (NASDAQ:FATE) last released its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.03. Fate Therapeutics had a negative return on equity of 90.94% and a negative net margin of 699.10%. The company had revenue of $1.03 million for the quarter, compared to analysts’ expectations of $1.02 million. Equities analysts forecast that Fate Therapeutics Inc. will post ($1.12) earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Spark Investment Management LLC boosted its position in Fate Therapeutics by 1.8% in the first quarter. Spark Investment Management LLC now owns 63,700 shares of the biopharmaceutical company’s stock worth $114,000 after buying an additional 1,100 shares during the period. Bank of New York Mellon Corp raised its stake in Fate Therapeutics by 7.8% in the second quarter. Bank of New York Mellon Corp now owns 68,444 shares of the biopharmaceutical company’s stock worth $117,000 after buying an additional 4,941 shares in the last quarter. BlackRock Institutional Trust Company N.A. raised its stake in Fate Therapeutics by 66.0% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 69,394 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 27,578 shares in the last quarter. BlackRock Fund Advisors raised its stake in Fate Therapeutics by 26.2% in the second quarter. BlackRock Fund Advisors now owns 75,572 shares of the biopharmaceutical company’s stock worth $128,000 after buying an additional 15,701 shares in the last quarter. Finally, Emerald Acquisition Ltd. bought a new stake in Fate Therapeutics during the second quarter worth $137,000. Institutional investors own 48.71% of the company’s stock.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
Receive News & Ratings for Fate Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.